DelveInsight’s “Von Willebrand disease (VWD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Von Willebrand disease (VWD), historical and forecasted epidemiology as well as the Von Willebrand disease (VWD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Highlights
Key Companies working on Von Willebrand Disease include Vega Therapeutics, Archemix, Octapharma, CSL Behring, Grifols Therapeutics LLC, and many others.
Key Therapies included in the Von Willebrand Disease market include Voncento, Wilate, and many others.
Von Willebrand Disease Overview
Von Willebrand Disease is an acute viral hemorrhagic disease transmitted by infected mosquitoes. The “yellow” in the name refers to the jaundice that affects some patients. Symptoms of Von Willebrand Disease include fever, headache, jaundice, muscle pain, nausea, vomiting, and fatigue.
Von Willebrand Disease is a viral disease of typically short duration.In most cases, symptoms include fever, chills, loss of appetite, nausea, muscle pains – particularly in the back – and headaches. Symptoms typically improve within five days.In about 15% of people, within a day of improving the fever comes back, abdominal pain occurs, and liver damage begins causing yellow skin. If this occurs, the risk of bleeding and kidney problems is increased.
The disease is caused by the Von Willebrand Disease virus and is spread by the bite of an infected mosquito. It infects humans, other primates, and several types of mosquitoes. In cities, it is spread primarily by Aedes aegypti, a type of mosquito found throughout the tropics and subtropics. The virus is an RNA virus of the genus Flavivirus The disease may be difficult to tell apart from other illnesses, especially in the early stages. To confirm a suspected case, blood-sample testing with a polymerase chain reaction is required.
Von Willebrand Disease Epidemiology Insights
Globally 0.6–1.3% of the general population was affected by VWD (unspecified data source and time period), and the prevalence of symptomatic VWD was approximately 10 per 100,000.
Click here to learn more about the Von Willebrand Disease Market Landscape
The Report Covers the Von Willebrand Disease Epidemiology Segmented by:
Von Willebrand Disease prevalent cases
Von Willebrand Disease incident cases
Von Willebrand Disease treatment cases
Von Willebrand Disease diagnosed cases
Von Willebrand Disease Market Outlook
The Von Willebrand Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Von Willebrand Disease market trends by analyzing the impact of current Von Willebrand Disease therapies on the market, Von Willebrand Disease unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Von Willebrand Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Von Willebrand Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Von Willebrand Disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Von Willebrand Disease Market
Vega Therapeutics
Archemix
Octapharma
CSL Behring
Grifols Therapeutics LLC
And many others
Von Willebrand Disease Therapies Covered and Analyzed in the Report
Voncento
Wilate
Learn more about the Key Companies and Emerging Therapies in the Von Willebrand Disease Market
Table of Contents
Key Insights
Von Willebrand Disease Introduction
Executive Summary of Von Willebrand Disease
Disease Background and Overview
Epidemiology and patient population
Von Willebrand Disease Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Von Willebrand Disease Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
